GSK Strikes Deals With Vernalis, Nabi | August 17, 2009 Issue - Vol. 87 Issue 33 | Chemical & Engineering News
Volume 87 Issue 33 | p. 18 | Concentrates
Issue Date: August 17, 2009

GSK Strikes Deals With Vernalis, Nabi

Department: Business
Keywords: GSK, Vernalis, Nabi, pharmaceuticals

GlaxoSmithKline will collaborate with Vernalis to develop drugs that act against an undisclosed oncology target. Under the deal, Vernalis will receive $6 million up front and could get milestone payments exceeding $200 million. Vernalis will apply its structure-based drug-design technique to advance small-molecule drug candidates. Separately, GSK has acquired Nabi Pharmaceuticals’ PentaStaph for up to $45 million. PentaStaph is a vaccine being developed against Staphylococcus aureus, a multi-drug-resistant bacterium.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment